# Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors

Source: https://onco.cc/trials/nct07073534/  
OnCo record `nct07073534` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Adebrelimab and SHR-1501 in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.

## Summary

Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors is a phase 1/2 interventional study registered as NCT07073534 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 203 participants planned, started 2025-07-24 and due to reach its primary completion in 2027-12. Interventions recorded: SHR-1501, Adebrelimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07073534
- Phase: 1/2
- Setting: Phase I/II Clinical Study on the Tolerability, Safety and Efficacy of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
- Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Enrolled: 203

## Sources

- ClinicalTrials.gov NCT07073534: https://clinicaltrials.gov/study/NCT07073534

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [SHR-1501](https://onco.cc/drugs/shr-1501/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07073534.json